
Purpose: Iodine contrast enhancement is assessed using computed tomography (CT) number, though this value is not proportional to iodine concentration. This study develops a metric for iodine enhancement that is directly proportional to iodine concentration. Materials and Methods: Using studies previously reported in the literature, we parameterized the effect to create a correction for tube potential and patient-size-specific beam hardening on iodine CT number decrease. To validate the correction, we performed a study using different iodine concentrations, phantom sizes, and tube potentials. We also applied the correction to patient pulmonary angiogram data. Patients were grouped by tube potential [80, 100, 120, 140] (kV). Quantitative iodine contrast enhancement (Q-ICE) (ie, the difference between noncontrast and contrast-enhanced CT number) of the pulmonary artery (PA) was calculated. Pearson correlation coefficients are reported to characterize trends in PA Q-ICE across weight before and after correction. Results: The range of CT numbers measured for [10, 15] mg/mL iodine inserts was [290, 433] HU before correction, and [24, 36] HU after correction. Before correction, median PA Q-ICE enhancement was [662, 490, 263, 175] HU for [80, 100, 120, 140] kV, with a range of 487 HU observed across all measurements. After correction, the median PA Q-ICE enhancement was [366, 373, 285, 249] HU, with a range of 124 HU. Pearson correlation coefficients significantly ( P < 0.05) decreased after correction from -0.67 to -0.37. Conclusions: This study demonstrated a method to normalize effects of tube potential and beam hardening on CT number, yielding a metric proportional to iodine concentration.
PURPOSE: Coronary artery calcium (CAC) visually estimated on non-electrocardiogram (ECG)-gated chest CTs is reported inconsistently, limiting identification of high-risk individuals. Although automated AI-derived CAC scoring offers the potential to standardize reporting and improve reliability, this method warrants rigorous validation. MATERIALS AND METHODS: Three hundred thirty-two patients (59% female, median age 62) who underwent a non-gated chest CT within 1-year of a dedicated cardiac CT with Agatston's CAC score (CACscore) were identified between 2016 and 2022. AI-Rad Companion (Siemens) was used to compute CAC volume (AI-CACvol). AI-CACvol performance was compared with radiologists' qualitative CAC reports (H-CACqual) using optimized thresholds for identifying actionable CAC. Model performance was further validated in a postimplementation population. RESULTS: Median AI-CACvol was 20.3 mm³ (IQR 0-188.65), strongly correlated with CACscore (Spearman ρ=0.91, 95% CI: 0.88-0.94); median 31.55 Agatston Units (AU), IQR: 0 to 250). Agreement with CACscore was higher for AI-CACvol versus H-CACqual (weighted kappa 0.88, 95% CI: 0.84, 0.91; vs. 0.85, 95% CI: 0.82, 0.88; P=0.022). At a cutoff of 70 mm³, AI-CACvol demonstrated superior sensitivity compared with H-CACqual for detecting CAC≥100 AU, with greater sensitivity (95% vs. 75%) and comparable specificity (92% vs. 94%). In a validation cohort of 39 patients (64% female, median age 67 y), median CACscore was 43 AU (IQR 0-215) and median AI-CACvol 29.7 mm³ (IQR: 0 to 219.4). The same 70 mm³ cutoff achieved 100% sensitivity and 88% specificity for CAC≥100 AU (n=13). CONCLUSION: AI-derived CAC volume from non-gated chest CTs correlates strongly with reference CAC scores, showing high sensitivity at actionable thresholds. This supports potential opportunistic screening, though impact on outcomes requires study.
Purpose: Coronary artery calcium (CAC) visually estimated on non-electrocardiogram (ECG)-gated chest CTs is reported inconsistently, limiting identification of high-risk individuals. Although automated AI-derived CAC scoring offers the potential to standardize reporting and improve reliability, this method warrants rigorous validation. Materials and Methods: Three hundred thirty-two patients (59% female, median age 62) who underwent a non-gated chest CT within 1-year of a dedicated cardiac CT with Agatston’s CAC score (CACscore) were identified between 2016 and 2022. AI-Rad Companion (Siemens) was used to compute CAC volume (AI-CACvol). AI-CACvol performance was compared with radiologists’ qualitative CAC reports (H-CACqual) using optimized thresholds for identifying actionable CAC. Model performance was further validated in a postimplementation population. Results: Median AI-CACvol was 20.3 mm³ (IQR 0-188.65), strongly correlated with CACscore (Spearman ρ=0.91, 95% CI: 0.88-0.94); median 31.55 Agatston Units (AU), IQR: 0 to 250). Agreement with CACscore was higher for AI-CACvol versus H-CACqual (weighted kappa 0.88, 95% CI: 0.84, 0.91; vs. 0.85, 95% CI: 0.82, 0.88; P =0.022). At a cutoff of 70 mm³, AI-CACvol demonstrated superior sensitivity compared with H-CACqual for detecting CAC≥100 AU, with greater sensitivity (95% vs. 75%) and comparable specificity (92% vs. 94%). In a validation cohort of 39 patients (64% female, median age 67 y), median CACscore was 43 AU (IQR 0-215) and median AI-CACvol 29.7 mm³ (IQR: 0 to 219.4). The same 70 mm³ cutoff achieved 100% sensitivity and 88% specificity for CAC≥100 AU (n=13). Conclusion: AI-derived CAC volume from non-gated chest CTs correlates strongly with reference CAC scores, showing high sensitivity at actionable thresholds. This supports potential opportunistic screening, though impact on outcomes requires study.
Hypertrophic heart disease comprises a heterogeneous group of myocardial disorders characterized by increased left ventricular wall thickness arising from diverse pathologic processes. Despite differing etiologies, these diseases frequently demonstrate overlapping phenotypic features, which can create significant diagnostic challenges. Accurate differentiation is clinically important, given the prognostic implications associated with each condition, and the application of disease-specific therapeutic strategies. Cardiovascular magnetic resonance (CMR) has become central to the evaluation of hypertrophic heart disease due to its high spatial resolution and unique capability for comprehensive multiparametric tissue characterization. Beyond standardized assessment of ventricular volumes, function, mass, and wall thickness, CMR provides detailed characterization of myocardial fibrosis, edema, and tissue composition through late gadolinium enhancement imaging and parametric mapping techniques, including native T1, T2, and extracellular volume mapping. This review summarizes the contemporary role of CMR in the assessment of hypertrophic heart diseases, with emphasis on imaging features that aid differential diagnosis, and clinically relevant findings that influence management and prognosis.